Fenorovan
MarketedCombination dyslipidaemia drug launched in April 2026.
FROM PUBLIC EVENTS · 2026-11-15
Early clinical · first deals Launching a series of chronic-disease combination drugs while preparing the first trial of a once-monthly obesity candidate. Also seen: Commercial · sales
Roles often seen at this stageResearch & development · Clinical & PV · Sales & marketing
A maker of chronic-disease medicines such as combination drugs for hypertension, dyslipidaemia and diabetes, plus over-the-counter products, co-developing a once-monthly obesity candidate.
Combination dyslipidaemia drug launched in April 2026.
Once-monthly semaglutide obesity candidate for which a Phase 1 trial plan has been filed.
Presented results for its once-monthly obesity candidate at the American Diabetes Association meeting.
Official role guide
Observed 2026-11-15
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.